Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches

被引:18
作者
Tripathy, Dev Kumar [1 ]
Panda, Lakshmi Priya [1 ]
Biswal, Suryanarayan [2 ]
Barhwal, Kalpana [1 ]
机构
[1] All India Inst Med Sci AIIMS, Dept Physiol, Bhubaneswar, India
[2] Cent Univ Punjab, Dept Human Genet & Mol Med, Bathinda, India
关键词
glioblastoma; tumor microenvironment; angiogenesis; immunotherapy; blood-brain barrier; therapeutic approaches; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NEWLY-DIAGNOSED GLIOBLASTOMA; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; MESSENGER-RNA EXPRESSION; GLIOMA-CELLS; PHASE-II; TGF-BETA; MATRIX METALLOPROTEINASES;
D O I
10.3389/fphar.2024.1355242
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glioblastoma (GB) is an intrusive and recurrent primary brain tumor with low survivability. The heterogeneity of the tumor microenvironment plays a crucial role in the stemness and proliferation of GB. The tumor microenvironment induces tumor heterogeneity of cancer cells by facilitating clonal evolution and promoting multidrug resistance, leading to cancer cell progression and metastasis. It also plays an important role in angiogenesis to nourish the hypoxic tumor environment. There is a strong interaction of neoplastic cells with their surrounding microenvironment that comprise several immune and non-immune cellular components. The tumor microenvironment is a complex network of immune components like microglia, macrophages, T cells, B cells, natural killer (NK) cells, dendritic cells and myeloid-derived suppressor cells, and non-immune components such as extracellular matrix, endothelial cells, astrocytes and neurons. The prognosis of GB is thus challenging, making it a difficult target for therapeutic interventions. The current therapeutic approaches target these regulators of tumor micro-environment through both generalized and personalized approaches. The review provides a summary of important milestones in GB research, factors regulating tumor microenvironment and promoting angiogenesis and potential therapeutic agents widely used for the treatment of GB patients.
引用
收藏
页数:18
相关论文
共 190 条
[31]   The Blood-Brain Barrier [J].
Daneman, Richard ;
Prat, Alexandre .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2015, 7 (01)
[32]   Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma [J].
de Groot, J. F. ;
Gilbert, M. R. ;
Aldape, K. ;
Hess, K. R. ;
Hanna, T. A. ;
Ictech, S. ;
Groves, M. D. ;
Conrad, C. ;
Colman, H. ;
Puduvalli, V. K. ;
Levin, V. ;
Yung, W. K. A. .
JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :89-97
[33]   Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy [J].
Dunn, J. ;
Baborie, A. ;
Alam, F. ;
Joyce, K. ;
Moxham, M. ;
Sibson, R. ;
Crooks, D. ;
Husband, D. ;
Shenoy, A. ;
Brodbelt, A. ;
Wong, H. ;
Liloglou, T. ;
Haylock, B. ;
Walker, C. .
BRITISH JOURNAL OF CANCER, 2009, 101 (01) :124-131
[34]   GLIOBLASTOMA MULTIFORME - ANALYSIS OF RESULTS OF POSTOPERATIVE RADIOTHERAPY ALONE VERSUS RADIOTHERAPY AND CONCOMITANT 5-FLUOROURACIL - PROSPECTIVE RANDOMIZED STUDY OF 32 CASES [J].
EDLAND, RW ;
JAVID, M ;
ANSFIELD, FJ .
AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1971, 111 (02) :337-&
[35]   The biology of brain metastases-translation to new therapies [J].
Eichler, April F. ;
Chung, Euiheon ;
Kodack, David P. ;
Loeffler, Jay S. ;
Fukumura, Dai ;
Jain, Rakesh K. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (06) :344-356
[36]   GLUCOCORTICOID RECEPTORS IN GLIOBLASTOMA-MULTIFORME - A NEW APPROACH TO ANTINEOPLASTIC GLUCOCORTICOID THERAPY [J].
ELLEMANN, K ;
CHRISTENSEN, L ;
GJERRIS, F ;
BRIAND, P ;
KRUSELARSEN, C .
ACTA NEUROCHIRURGICA, 1988, 93 (1-2) :6-9
[37]   Transplanted glioma cells migrate and proliferate on host brain vasculature: A dynamic analysis [J].
Farin, A ;
Suzuki, SO ;
Weiker, M ;
Goldman, JE ;
Ruce, JN ;
Canoll, P .
GLIA, 2006, 53 (08) :799-808
[38]   Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. [J].
Fecci, PE ;
Mitchell, DA ;
Whitesides, JF ;
Xie, WH ;
Friedman, AH ;
Archer, GE ;
Herndon, JE ;
Bigner, DD ;
Dranoff, G ;
Sampson, JH .
CANCER RESEARCH, 2006, 66 (06) :3294-3302
[39]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[40]   Angiogenesis as a therapeutic target [J].
Ferrara, N ;
Kerbel, RS .
NATURE, 2005, 438 (7070) :967-974